Global Transfusion Diagnosis for Donor Market Strategic Research Report

Scope of the Report

The global Transfusion Diagnosis for Donor market size is predicted to grow from US$ 4,402 million in 2025 to US$ 6,479 million in 2032; it is expected to grow at a CAGR of 5.7% from 2026 to 2032.

The gross profit margin of major companies in the industry is between 50% – 70%.

Transfusion Diagnosis for Donors refers to the critical medical screening and testing process performed on blood donors to ensure the safety and compatibility of blood products. This includes mandatory screening for transfusion-transmitted infections (TTIs) such as HIV, Hepatitis B and C, and Syphilis using Nucleic Acid Testing (NAT) and ELISA. It also encompasses blood group serology (ABO/Rh typing) and cross-matching. These procedures are fundamental to modern hemovigilance, ensuring every blood unit meets stringent clinical safety standards to prevent adverse reactions in recipients.

The industrial chain begins upstream with providers of biological raw materials (antigens, antibodies, enzymes), precision optical sensors, microfluidic chips, and high-purity reagents. The midstream consists of manufacturers of automated blood screening platforms, molecular diagnostic systems, and immunoassays. Downstream applications include national and regional blood centers, hospital blood banks, and plasma collection stations. The chain is supported by cold-chain logistics providers and regulatory bodies. Service providers offer calibration, system maintenance, and integrated blood management software to track blood units from collection to clinical transfusion, ensuring full traceability and safety.

The market for transfusion diagnosis is witnessing a significant shift toward automated and molecular-based testing to minimize the "window period" of infection detection. Increasing global healthcare expenditures and aging populations are driving the demand for safe blood supplies. A key trend is the integration of Nucleic Acid Testing (NAT) with traditional serology to enhance sensitivity. Furthermore, the adoption of Big Data and AI in blood management systems is optimizing inventory and reducing wastage. While stringent regulatory requirements pose a high entry barrier, the expansion of blood banking infrastructure in emerging economies provides substantial growth opportunities. Manufacturers are focusing on high-throughput systems that reduce manual errors while maintaining the highest levels of diagnostic accuracy and safety.

This report presents a comprehensive overview of the global Transfusion Diagnosis for Donor market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Instruments
• Kits and Reagents

Segment by Diagnostic Purpose

• Blood Grouping & Typing Diagnostics
• Infectious Disease Screening Diagnostics

Segment by Testing Method

• Immunoassay-Based Diagnostics
• Molecular Diagnostics

Segment by Application

• Blood Banks
• Blood Donation/Transfusion Centers
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Transfusion Diagnosis for Donor market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Blood Banks, Blood Donation/Transfusion Centers, Others evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact